Journal
BIOMEDICINES
Volume 9, Issue 3, Pages -Publisher
MDPI
DOI: 10.3390/biomedicines9030248
Keywords
NAFLD; extra-hepatic outcome; organ-on-a-chip; artificial intelligence
Categories
Funding
- AGAUR (Generalitat de Catalunya) [2019 LLAV 00056]
- European Community under the Catalonian ERDF operational program (European Regional Development Fund) 2014-2020
- European Research Council program under grants ERC-StG-DAMOC [714317]
- Spanish Ministry of Economy and Competitiveness, through the Severo Ochoa Program for Centres of Excellence in RD [SEV-2016-2019]
- Spanish Ministry of Economy and Competitiveness, through the Retos de investigacion: Proyectos I+D+i [TEC2017-83716-C2-2-R]
- CERCA Programme/Generalitat de Catalunya [2014-SGR-1460]
- Fundacion Bancaria la Caixa-Obra Social la Caixa (project IBEC-La Caixa Healthy Ageing)
- European Research Council (ERC) [714317] Funding Source: European Research Council (ERC)
Ask authors/readers for more resources
Non-alcoholic fatty liver affects a significant portion of the global adult population and can lead to severe complications. Organ-on-chips combined with artificial intelligence offer a promising approach to uncover potential therapeutic targets and understand the complex mechanisms of NAFLD.
Non-alcoholic fatty liver affects about 25% of global adult population. On the long-term, it is associated with extra-hepatic compliances, multiorgan failure, and death. Various invasive and non-invasive methods are employed for its diagnosis such as liver biopsies, CT scan, MRI, and numerous scoring systems. However, the lack of accuracy and reproducibility represents one of the biggest limitations of evaluating the effectiveness of drug candidates in clinical trials. Organ-on-chips (OOC) are emerging as a cost-effective tool to reproduce in vitro the main NAFLD's pathogenic features for drug screening purposes. Those platforms have reached a high degree of complexity that generate an unprecedented amount of both structured and unstructured data that outpaced our capacity to analyze the results. The addition of artificial intelligence (AI) layer for data analysis and interpretation enables those platforms to reach their full potential. Furthermore, the use of them do not require any ethic and legal regulation. In this review, we discuss the synergy between OOC and AI as one of the most promising ways to unveil potential therapeutic targets as well as the complex mechanism(s) underlying NAFLD.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available